Partnerships update-July 2022

Partnerships update-July 2022

July has provided an opportunity for the Partnerships team to take stock of the amazing innovations our platforms have been able to deliver due to our supporters. As we move towards a well-deserved summer break, we want to remind our followers of some of the key features that have been added to our platforms throughout the first half of 2022. 

Google Translate  

Our platforms have a global audience, with our content reaching over 161 countries. It has become crucial that access to our wide range of content is made as broad as possible; therefore, the introduction of Google Translate has advanced this. Google Translate enables content to be translated to over 100 languages, including Punjabi, Japanese, and Arabic. 

Pre- and post-learning tests  

Our quiz questions are designed to aid the learning journey in accordance with our learning objectives and are intended as a fun challenge for readers, providing them with the opportunity to test their knowledge, improve on their pre-content quiz score, and compare themselves to the average score of their colleagues. The quizzes also allow us to measure the effectiveness of our education. This is critical in enabling us to observe any persisting gaps/educational needs and to continually monitor our educational design to ensure it meets the needs of our readers optimally. 

Drug update Twitter feed 

Our hub Twitter channels are a fantastic source of information and updates for the community. We are now pleased to be able to host our medical update Twitter feeds directly on the hub websites. The drug update tabs can be viewed for the latest bite-sized news in clinical developments and regulatory updates.  



World ALL Day (September 20, 2022): Know your subtype 

Through a successful collaboration, Know ALL, SES, and the Acute Leukemia Advocates Network (ALAN) are working together to host an inaugural World ALL Day. This event will be held on September 20, 2022, and as the first event of its kind, its aim is to mobilize patients, carers, and HCPs and increase the awareness of acute lymphoblastic leukemia (ALL). 

The “Know your subtype” campaign delivered throughout the day will encourage patients to share their subtype and share their story in order to help increase knowledge of different ALL subtypes and how they are classified among the community.  

If you would like more information on how to support World ALL Day or the Know ALL initiative, please contact 

MDS International Guidelines 

The MDS International Guidelines project is a global project that is being developed with the mission of raising the standards of disease management in myelodysplastic syndromes (MDS) globally through the development of contemporary and practical MDS treatment guidelines. 

Hosted on a web-based, multichannel, open-access platform, the guidelines will be available in a responsive format suitable for phones, tablets, and computers. It’s hoped the mobile responsiveness can be utilized to encourage daily use within clinical practice. We are seeking industry support to ensure this project delivers upon its full potential and generates a comprehensive set of clinically advocated guidelines for use in the frontline hematology setting. 

Please contact for further information on how to get involved.  

SES at the International Myeloma Society (August 25–27)  

Partnership Director, Ken Zangina, alongside Indication Lead, Marta Llobet, will be attending the International Myeloma Society congress in Los Angeles on August 25–27, where they are looking forward to meeting key industry stakeholders within multiple myeloma. They also look forward to meeting with existing supporters and potential partners of the Multiple Myeloma Hub. 

To arrange a meeting and to receive a Multiple Myeloma Hub update, please contact 



MPN Hub  

We are delighted to confirm that Sierra Oncology will be continuing its support of the MPN Hub. Through becoming a Bronze supporter, Sierra Oncology’s support will contribute towards enabling growth of the MPN Hub, which will continue to highlight the breadth of treatment options available for patients with myelofibrosis and other types of MPN.  

ALL Hub 

We are delighted to announce that Amgen will be continuing to support the ALL Hub as a Silver supporter. As a leading stakeholder in the care of patients with ALL, we are pleased Amgen have reaffirmed their support for the platform.  



We are seeking grants from our existing and new industry partners to support the delivery of new and innovative educational learning interventions for the hematology community. Through the delivery of these bespoke initiatives across our established learning platforms, we hope to demonstrate advanced levels of learning in targeted areas of unmet needs relevant to HCPs.  

CAR T-cell therapy (a multi-platform webinar series from the Lymphoma Hub, Multiple Myeloma Hub, and ALL Hub)  

In a first for our hematology hubs, this webinar series will address unmet educational needs pertaining to the growing scope of CAR-T cell therapies across the hematology indications. With consideration of the complex treatment journey, from the initial consultation through to transition of care, this project aims to support HCPs involved in this new and evolving treatment area, enabling them to make optimal treatment choices for their patients. Leveraging the remarkable reach of three relevant hub platforms, the content will also remain on the platforms as a valuable source of enduring content.  

Beyond JAK inhibition: Novel agents for the treatment of advanced myelofibrosis (a clinical trial club)  

Following the success of our first clinical trial club webinar, which focussed on navtemadlin, we hope to provide further webinars within this series to highlight other novel agents for the treatment of advanced myelofibrosis. 

A clinical trial club is a live webinar where one of our steering committee members is joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trial clubs effectively support HCPs in understanding what the latest news means for clinical practice. They offer the ideal solution to address the key learning gap of suboptimal knowledge of novel therapeutic targets in MPN. 

Sequencing of therapies in acute lymphoblastic leukemia (a case-based symposium) 

This case-based symposium will discuss the issues associated with the sequencing of therapies for B-cell ALL. A panel of selected ALL Hub key opinion leaders will discuss cases related to this subtype of the disease.

Pre- and post-case discussions will help develop the viewers’ understanding of the recommended treatment algorithm in these cases, and viewer interactivity with the panel will help raise confidence and competence in their management of the disease. We are seeking support from industry stakeholders to enable the delivery of this learning initiative.  

If you would like to learn more about supporting these educational initiatives, please contact the Partnerships team at